Advertisement

Oral Manifestations of Autoimmune and Connective Tissue Disorders

      Immune system malfunction is the underlying cause of symptoms in autoimmune, autoinflammatory and connective tissue disorders.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      References

        • Sticherling M.
        • Erfurt-Berge C.
        Autoimmune blistering diseases of the skin.
        Autoimmun Rev. 2012; 11: 226-230
        • Mustafa M.B.
        • Porter S.R.
        • Smoller B.R.
        • et al.
        Oral mucosal manifestations of autoimmune skin diseases.
        Autoimmun Rev. 2015; 14: 930-951
        • Ali S.
        • Kelly C.
        • Challacombe S.J.
        • et al.
        Salivary IgA and IgG antibodies to bullous pemphigoid 180 noncollagenous domain 16a as diagnostic biomarkers in mucous membrane pemphigoid.
        Br J Dermatol. 2016; 174: 1022-1029
        • Huang A.
        • Madan R.K.
        • Levitt J.
        Future therapies for pemphigus vulgaris: rituximab and beyond.
        J Am Acad Dermatol. 2016; 74: 746-753
        • Ali S.
        • Kelly C.
        • Challacombe S.J.
        • et al.
        Serum and salivary IgG and IgA antibodies to desmoglein 3 in mucosal pemphigus vulgaris.
        Br J Dermatol. 2016; 175: 113-121
        • Bernard P.
        • Vaillant L.
        • Labeille B.
        • et al.
        Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group.
        Arch Dermatol. 1995; 131: 48-52
        • Bertram F.
        • Brocker E.-B.
        • Zillikens D.
        • et al.
        Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany.
        J Dtsch Dermatol Ges. 2009; 7: 434-440
        • Chan L.S.
        Ocular and oral mucous membrane pemphigoid (cicatricial pemphigoid).
        Clin Dermatol. 2012; 30: 34-37
        • Thorne J.E.
        • Anhalt G.J.
        • Jabs D.A.
        Mucous membrane pemphigoid and pseudopemphigoid.
        Ophthalmology. 2004; 111: 45-52
        • Taylor J.
        • McMillan R.
        • Shephard M.
        • et al.
        World Workshop on Oral Medicine VI: a systematic review of the treatment of mucous membrane pemphigoid.
        Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 120: 161-171.e20
        • Al-Shehhi F.
        • Balakirski G.
        • Baratli J.
        • et al.
        Localized oral mucous membrane pemphigoid: successful topical treatment with 1% tacrolimus solution as steroid-sparing therapy.
        J Eur Acad Dermatol Venereol. 2016; 31: e176-e178
        • Kalinska-Bienias A.
        • Kalowska M.
        • Kwiek B.
        • et al.
        Efficacy and safety of perilesional/intralesional triamcinolone injections in oral mucous membrane pemphigoid.
        Br J Dermatol. 2016; 174: 436-438
        • McCartan B.E.
        • Healy C.M.
        The reported prevalence of oral lichen planus: a review and critique.
        J Oral Pathol Med. 2008; 37: 447-453
        • Payeras M.R.
        • Cherubini K.
        • Figueiredo M.A.
        • et al.
        Oral lichen planus: focus on etiopathogenesis.
        Arch Oral Biol. 2013; 58: 1057-1069
        • DeRossi S.S.
        • Ciarrocca K.N.
        Lichen planus, lichenoid drug reactions, and lichenoid mucositis.
        Dent Clin North Am. 2005; 49 (viii): 77-89
        • Zeidan M.J.
        • Saadoun D.
        • Garrido M.
        • et al.
        Behcet’s disease physiopathology: a contemporary review.
        Auto Immun Highlights. 2016; 7: 4
        • Sakane T.
        • Takeno M.
        • Suzuki N.
        • et al.
        Behcet’s disease.
        N Engl J Med. 1999; 341: 1284-1291
      1. Criteria for diagnosis of Behcet’s disease. International study group for Behcet’s disease.
        Lancet. 1990; 335: 1078-1080
        • Davatchi F.
        • Assaad-Khalil S.
        • Calamia K.T.
        • et al.
        The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria.
        J Eur Acad Dermatol Venereol. 2014; 28: 338-347
        • Khatibi M.
        • Shakoorpour A.H.
        • Jahromi Z.M.
        • et al.
        The prevalence of oral mucosal lesions and related factors in 188 patients with systemic lupus erythematosus.
        Lupus. 2012; 21: 1312-1315
        • Somers E.C.
        • Marder W.
        • Cagnoli P.
        • et al.
        Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program.
        Arthritis Rheumatol. 2014; 66: 369-378
        • Brennan M.T.
        • Valerin M.A.
        • Napenas J.J.
        • et al.
        Oral manifestations of patients with lupus erythematosus.
        Dent Clin North Am. 2005; 49 (ix): 127-141
        • Helmick C.G.
        • Felson D.T.
        • Lawrence R.C.
        • et al.
        Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.
        Arthritis Rheum. 2008; 58: 15-25
        • Ramos-Casals M.
        • Brito-Zeron P.
        • Kostov B.
        • et al.
        Google-driven search for big data in autoimmune geoepidemiology: analysis of 394,827 patients with systemic autoimmune diseases.
        Autoimmun Rev. 2015; 14: 670-679
        • Campos J.
        • Hillen M.R.
        • Barone F.
        Salivary gland pathology in Sjogren’s syndrome.
        Rheum Dis Clin North Am. 2016; 42: 473-483
        • Shiboski C.H.
        • Shiboski S.C.
        • Seror R.
        • et al.
        2016 American College of Rheumatology/European League against Rheumatism classification criteria for primary Sjogren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts.
        Ann Rheum Dis. 2017; 76: 9-16
        • Carsons S.E.
        • Vivino F.B.
        • Parke A.
        • et al.
        Treatment guidelines for rheumatologic manifestations of Sjogren’s: use of biologics, management of fatigue and inflammatory musculoskeletal pain.
        Arthritis Care Res (Hoboken). July 2016; 69: 517-527
        • Zero D.T.
        • Brennan M.T.
        • Daniels T.E.
        • et al.
        Clinical practice guidelines for oral management of Sjogren disease: dental caries prevention.
        J Am Dent Assoc. 2016; 147: 295-305
        • Smolen J.S.
        • Aletaha D.
        • McInnes I.B.
        Rheumatoid arthritis.
        Lancet. 2016; 388: 2023-2038
        • Yamakawa M.
        • Ansai T.
        • Kasai S.
        • et al.
        Dentition status and temporomandibular joint disorders in patients with rheumatoid arthritis.
        Cranio. 2002; 20: 165-171
        • Kurtoglu C.
        • Kurkcu M.
        • Sertdemir Y.
        • et al.
        Temporomandibular disorders in patients with rheumatoid arthritis: a clinical study.
        Niger J Clin Pract. 2016; 19: 715-720
        • Gerke A.K.
        Morbidity and mortality in sarcoidosis.
        Curr Opin Pulm Med. 2014; 20: 472-478
      2. Orphanet report series. Prevalence of rare diseases: Bibliographic data. November 2016, Number 1. Available at: http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf. Accessed May 24, 2017.

        • Erdal B.S.
        • Clymer B.D.
        • Yildiz V.O.
        • et al.
        Unexpectedly high prevalence of sarcoidosis in a representative U.S. Metropolitan population.
        Respir Med. 2012; 106: 893-899
        • Valeyre D.
        • Prasse A.
        • Nunes H.
        • et al.
        Sarcoidosis.
        Lancet. 2014; 383: 1155-1167
      3. NHLBI workshop on sarcoidosis. Leveraging scientific advancements to understand sarcoidosis variability and improve outcomes. August 31st – September 1st 2015. Available at: https://www.nhlbi.nih.gov/research/reports/nhlbi-workshop-sarcoidosis-%E2%80%9Cleveraging-scientific-advancements-understand-sarcoidosis-variability. Accessed May 24, 2017.

        • Shah R.
        • Roberson G.H.
        • Cure J.K.
        Correlation of MR imaging findings and clinical manifestations in neurosarcoidosis.
        AJNR Am J Neuroradiol. 2009; 30: 953-961